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ABSTRACT 28 
Background Viral bronchiolitis is one of the most common causes of hospitalisation 29 
in young infants. It has previously been shown that many UK hospital Trusts were 30 
not compliant with many aspects of the NICE bronchiolitis guideline prior to its 31 
publication. 32 
Objectives This study aimed to investigate changes in the management of 33 
bronchiolitis by hospital Trusts between 2015 (before NICE guideline publication) 34 
and 2017, after publication.   35 
Study design We prospectively surveyed paediatricians at UK hospital Trusts on the 36 
management of bronchiolitis before (March to May 2015) and after (January to May 37 
2017) the NICE bronchiolitis guideline publication in June 2015, using an electronic, 38 
structured questionnaire.39 
Results In 2015 111 Trusts were represented and in 2017 100 Trusts. Significant 40 
improvements were seen in the use of nebulised bronchodilators and hypertonic 41 
saline and provision of parental written guidance.  However, full compliance with the 42 
guideline did not change with 18% of Trusts compliant before publication of the 43 
guideline in 2015 and 19% fully compliant with the guideline in 2017.  44 
Conclusions Overall there were modest but important improvements in the reported 45 
management of bronchiolitis after the publication of the NICE guideline. 46 
47 
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INTRODUCTION 49 
Viral bronchiolitis results in up to 25,000 hospital admissions per year in England 50 
with a 15-fold variation in hospital admission rates between different NHS Trusts 51 
across England [1]. Individual differences in hospital management have been 52 
suggested as a contributory factor to this variation [2].  The National Institute for 53 
Health and Care Excellence (NICE) published the first national (English) bronchiolitis 54 
guideline in June 2015 [3] to try to reduce this variation in management.  We have 55 
previously shown that many Trusts were not compliant with the NICE guideline prior 56 
to its’ publication [4], despite similar guidance already being available from the 57 
Scottish Intercollegiate Guideline Network (SIGN) [5].  This study investigates the 58 
changes in hospital Trust management after NICE guideline publication. 59 
60 
OBJECTIVES 61 
The aim of this study was to investigate changes in the management of bronchiolitis 62 
by hospital Trusts between 2015 (before NICE guideline publication) and 2017, after 63 
publication.  In our previous study we had also investigated the use of respiratory virus 64 
testing and isolation/cohorting of infants with viral bronchiolitis by Trusts and thus a 65 
secondary aim of this study was to assess any changes in these practices.  The data 66 
from the 2015 survey have been published previously [4]. 67 
68 
STUDY DESIGN 69 
A structured electronic questionnaire was sent to paediatricians from all Trusts in the 70 
UK that provide paediatric care (n=170) between March to May 2015 and January to 71 
4 
May 2017 as previously described [4].  It was sent as a link via e-mail to paediatric 72 
consultants and trainees working at each Trust. We compared the responses from 73 
Trusts in 2015 and 2017.  How many of the same clinicians completed the survey in 74 
both years is not known as the survey was completed anonymously but 42 Trusts 75 
had a participant complete the survey in both years. 76 
Statistical analysis 77 
Proportions were compared using the Chi squared or Fisher’s exact test.  Continuous 78 
variables were tested for normality using the Shapiro-Wilk test and data were analysed 79 
using either the independent T-test or the Mann-Whitney U test as appropriate. 80 
Statistical analysis was carried out with IBM SPSS Statistics (Version 24, New York, 81 
USA). 82 
Ethical approval was not required for this study. 83 
84 
RESULTS 85 
Demographics 86 
Of 100 the Trusts included in 2017, 75% were district general hospitals and 25% 87 
university hospitals. 99% of Trusts had an emergency department and 15% a 88 
paediatric intensive care unit (PICU). 50% of Trusts reported most children are 89 
initially seen by emergency doctors and 46% by paediatric doctors.   Responses 90 
were obtained from 87 (87%) general paediatric consultants, four (4%) respiratory 91 
consultants and nine (9%) junior doctors. All respondents were involved in the 92 
management of infants with acute bronchiolitis.   93 
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111 (65%) Trusts were represented by the responses in 2015 and 100 (59%) in 94 
2017. In 2015 100 (90%, 95% confidence interval [95% CI] 83-95%) Trusts had a 95 
guideline compared with 89 (89%, 95% CI 81-94%) in 2017, a difference of -1% 96 
(95% CI -9 to +7%, P=0.82). In 2017 58 (65%, 95% CI 55-74%) Trusts had updated 97 
their bronchiolitis guideline in light of the 2015 NICE guideline.  98 
Use of supplemental oxygen 99 
There was no significant change in the proportion of Trusts advising supplemental 100 
oxygen at the NICE recommended threshold of <92% after the guideline was 101 
published (58% versus 66%, Difference +8% [95% CI -6% to +21%], P=0.25). 102 
Intravenous (IV) fluids 103 
Most Trusts reserved IV fluids for infants with severe disease or other specific issues 104 
in both years (2015 versus 2017; 86% versus 96%, Difference +10% [95% CI 2-105 
19%], P=0.02). 106 
Chest physiotherapy and suctioning107 
Similar proportions of Trusts in 2015 and 2017 (26% versus 31%, Difference +5% 108 
[95% CI -7 to +18%], P=0.45) recommended undertaking chest physiotherapy only in 109 
specific circumstances (e.g. patients with difficulty clearing secretions) in line with the 110 
NICE recommendations.  111 
The proportion of Trusts recommending nasal suctioning for all hospitalised infants 112 
significantly decreased from 2015 to 2017 (39% versus 22%, Difference -17% [95% 113 
CI -4 to -29%], P=0.01) in line with the NICE recommendations. 114 
Investigations  115 
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The majority of Trusts only undertook blood gas testing (84% and 86% in 2015 and 116 
2017 respectively, Difference +2% [95% CI -8 to +12%], P=0.70) and chest x-rays 117 
(65% and 74% in 2015 and 2017 respectively, Difference +9% [95% CI -4 to +22%], 118 
P=0.18) in infants requiring high dependency unit (HDU) or paediatric intensive care 119 
unit (PICU) admission. 120 
Medications 121 
Between 2015 and 2017 there were improvements in the reported use of almost all 122 
medications not recommended by NICE (Table 1). 123 
Table 1: The number of Trusts advising against routine use of various medications in 124 
each year. Data presented as n (%, 95% confidence interval). 125 
Medication 2015 2017 % Difference P Value
Inhaled (via spacer) 
bronchodilator 
(NICE recommendation: Do 
not use salbutamol or 
ipratropium bromide) 
69 (69%, 
59-77%) 
72 (81%, 
72-88%) 
+12% (-0.5 to 
+24%) 
0.059 
Nebulised bronchodilator 
(NICE recommendation: Do 
not use salbutamol or 
ipratropium bromide) 
53 (53%, 
43-63%) 
62 (70%, 
59-78%) 
+17% (3-30%) 0.02 
Nebulised adrenaline 
(NICE recommendation: Do 
not use nebulised adrenaline) 
78 (78%, 
69-85%) 
78 (88%, 
72-93%) 
+10% (-1 to 
+20%) 
0.07 
Inhaled (via spacer) steroids 
(NICE recommendation: Do 
not use inhaled 
corticosteroids) 
95 (95%, 
89-98%) 
85 (96%, 
89-98%) 
+1% (-6 to 
+8%) 
0.74 
Nebulised steroids 
(NICE recommendation: Do 
not use inhaled 
corticosteroids) 
95 (95%, 
89-98%) 
87 (98%, 
92-99%) 
+3% (-3 to 
+9%) 
0.27 
Oral steroids 
(NICE recommendation: Do 
not use oral corticosteroids) 
93 (93%, 
86-97%) 
87 (98%, 
92-99%) 
+5% (-2 to 
+12%) 
0.10 
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Nebulised hypertonic saline 
(NICE recommendation: Do 
not use nebulised hypertonic 
saline) 
45 (45%, 
36-55%) 
60 (67%, 
57-76%) 
+22% (8-35%) 0.003 
Antibiotics 
(NICE recommendation: Do 
not use antibiotics) 
69 (69%, 
59-77%) 
72 (81%, 
72-88%) 
+12% (-0.5 to 
+24%) 
0.059 
Montelukast 
(NICE recommendation: Do 
not use montelukast) 
100 
(100%, 
96-100%)
87 (98%, 
92-99%) 
-2% (-7 to 
+2%) 
0.16 
Heliox 
(No NICE recommendation 
on Heliox) 
99 (99%, 
95-100%)
86 (97%, 
91-99%) 
-2% (-8 to 
+3%) 
0.32 
Ribavirin 
(No NICE recommendation 
on ribavirin) 
96 (96%, 
90-98%) 
83 (93%, 
86-97%) 
-3% (-11 to 
+4%) 
0.36 
126 
Written advice 127 
Significantly more Trusts routinely gave written information to parents in 2017 than 128 
2015 (51% versus 87%, Difference +36% [95% CI 23-47%], P<0.0001). 129 
Overall NICE guideline compliance 130 
There was no significant improvement in the proportion of Trusts that were fully 131 
compliant with the NICE guideline from 2015 to 2017 (18% versus 19%, Difference 132 
+1% [95% CI -10 to +12%], P=0.86).  Compliance with individual aspects of the 133 
NICE guideline ranged from 43% to 100% in 2015 and 52% to 97% in 2017. 134 
Respiratory viral testing  135 
The proportion of Trusts routinely testing hospitalised infants for respiratory viruses 136 
significantly decreased between 2015 and 2017 (72% versus 44%, Difference -27% 137 
[95% CI -14 to -39%], P=0.0001). 138 
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There was an increase in those Trusts only undertaking respiratory virus testing in 139 
infants with severe bronchiolitis (requiring HDU/PICU) (15% versus 40%, Difference 140 
25% [95% CI 13-36%], P<0.0001).  141 
Twenty-two (20%) Trusts in 2015 and 18 (18%) in 2017 (Difference -2% [95% CI -13 142 
to +9%], P=0.71) used respiratory syncytial virus (RSV) point of care tests in the 143 
emergency department (ED) to diagnose RSV infection as a cause of bronchiolitis. 144 
In 2015, 74 (68%) Trusts tested respiratory samples for RSV, influenza and other 145 
respiratory viruses, 28 (26%) for RSV only and four (4%) for RSV and influenza only 146 
compared with 52 (52%), 21 (21%) and 10 (10%) in 2017 respectively (P=0.10, 147 
comparing the mutually exclusive different options of testing between the years).  148 
Cohorting policies149 
Cohorting policies remained similar across the two years (P=0.46) (Table 2). 150 
Table 2: The number of Trusts using each of the different cohorting policies. Data 151 
presented as n (%, 95% confidence interval). The options were mutually exclusive. 152 
Cohorting policy 2015 2017 Difference P value*
All infants to 
individual 
rooms/cubicles 
39 (35%, 27-
45%) 
29 (29%, 21-
39%) 
-6% (-18 to 
+7%) 
0.46 
Cohort infants 
regardless of virus 
18 (16%, 11-
24%) 
15 (15%, 9-
23%) 
-1% (-11 to 
+9%) 
Cohort infants with 
the same virus 
18 (16%, 11-
24%) 
26 (26%, 18-
35%) 
+10% (-1 to 
21%) 
Cohort infants 
testing positive for 
RSV separate to 
infants testing 
positive for other 
viruses 
25 (23%, 16-
31%) 
19 (19%, 13-
28%) 
-4% (-15 to 
+7%) 
Other 10 (9%, 5-
16%) 
11 (11%, 6-
19%) 
+2% (-6 to 
+11%) 
9 
*The P value compares the five different cohorting options across the two years.  153 
154 
DISCUSSION 155 
In this study we demonstrated modest but significant improvements in Trusts’ 156 
reported management of viral bronchiolitis after the publication of the NICE 157 
guideline.  We have previously shown the NICE guideline resulted in similar modest 158 
improvements in the primary care management of bronchiolitis [6]. 159 
That only modest improvements are seen is not surprising given the relatively short 160 
time between the surveys, that there was already very high compliance in several 161 
areas and resistance to change and difficulties translating guidelines into clinical 162 
practice being long-recognised problems. To try to overcome these problems NICE 163 
recommends using questionnaires to obtain a clear picture of current practice [7], 164 
which was the aim of this study.  Widely distributed educational materials, regular 165 
national surveys and individual Trust audits are useful in helping adopt new 166 
guidelines into routine clinical practice [7].  We would welcome this for future updates 167 
of the NICE bronchiolitis guideline. 168 
The American Academy of Paediatrics published their bronchiolitis guideline in 2006. 169 
A large study investigated adherence to the guideline in three time cohorts; pre-170 
guideline, post-guideline early (one to two years post guideline) and post-guideline 171 
late (five to six years post guideline) [8]. There was minimal change between pre-172 
guideline and post-guideline early but significant reductions in the use of steroids 173 
and bronchodilators and number of blood tests and chest X-rays performed between 174 
the pre-guideline and post-guideline late groups. This suggests significant changes 175 
10 
take time to be adopted into clinical practice.  A Swiss study surveyed 1180 176 
paediatricians, and found that one to three years after publication of a bronchiolitis 177 
guideline with a national implementation strategy there were significant reductions in 178 
the use of bronchodilators and steroids [9], similar results to our study. 179 
Our study has several strengths and limitations. We have prospective, longitudinal 180 
data from a large number of Trusts representative of different size hospitals and 181 
geographic locations throughout the UK. Responses were only obtained from 182 
approximately 60% of relevant Trusts and thus it is possible that clinicians in higher 183 
performing Trusts may have been more likely to respond.  Individual patient notes 184 
were not examined and so we cannot comment on how these reported results 185 
translate to actual patient care. In addition, as some Trusts had replies from multiple 186 
clinicians which were not always identical, there may have been some individual 187 
clinician bias which may have resulted in either an under or over estimation of the 188 
use of investigations or non-recommended medications.  Forty-two Trusts completed 189 
the survey in both years, thus some differences may be due to variation in the others 190 
completing the survey in each year. 191 
Although it is recognised that guidelines are not always followed by individual 192 
clinicians, it remains important to establish Trusts’ recommendations as best 193 
practice. Many departments have high turnover of staff, particularly of junior doctors, 194 
and thus guidelines are an important tool in maintaining good clinical practice.  195 
In conclusion, modest but significant improvements in reported care have been 196 
made since the publication of NICE guideline. Given the high-volume nature of this 197 
condition, even small improvements may affect the care of large numbers of 198 
children. 199 
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